Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals with Newly Diagnosed Primary CNS Lymphoma
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI myeloMATCH Clinical Trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Tusamitamab Ravtansine (Tusa) Vs Investigator Choice in CEACAM5+ NSCLC After the Failure of Standard of Care Systemic Therapy
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
The Canadian Cancer Society (CCS) has launched its inaugural Data Transformation Grants to help transform cancer data and improve care. Apply for up to $125K for a 1-year project, from a funding envelope of ~$1M.
Please save the date for the 2022 Annual Spring Meeting of Participants which will be held in a virtual format again this year from Friday, April 29 to Sunday, May, 01.
The virtual spring meeting is the place for the network members to share ideas, work on trial concepts or ongoing studies, hear about the latest tools and approaches in cancer clinical research, and determine future research directions for the group. More information will be coming soon so stay tuned!
The Audit Group Team Leader will lead the Audit Team at CCTG to coordinate and implement audits of external participating clinical sites, external vendors and of internal processes to ensure compliance with applicable guidelines, regulations, standards and contractual requirements.
Reporting and accountable to the Manager, Early Drug Development Program (EDDP), the Trial Team Leader will lead one of several teams in Trial Management Group (TMG). Teams are comprised primarily of study coordinators, research associates, and clinical trials assistants, who are involved in the coordination of clinical trials in cancer therapy, prevention and supportive care.
Reporting to the Team Leader, Ethics and Regulatory, the Ethics Research Associate will assist to conduct the ethics responsibilities of the Ethics and Regulatory (ER) office, within the Canadian Cancer Trials Group (CCTG).